Febuxostat is a more selective and potent inhibitor of oxidase and has no effect on other enzymes involved in purine or pyrimidine metabolism. Febuxostat is well absorbed after oral administration. Febuxostat can be given without regard to food intake. The main route of elimination of Febuxostat is metabolism in the liver followed by excretion of metabolites in the urine and faeces.
Each film-coated tablet contains:
Colour: Red Oxide of Iron & Titanium Dioxide IP
MECHANISM OF ACTION:
Febuxostat is a novel, non–purine, selective xanthine oxidase inhibitor. Xanthine oxidase inhibitors reduce serum uric acid concentration by blocking the transformation of hypoxanthine to xanthine and of xanthine to uric acid. It forms a stable complex with both the reduced and oxidised form of the enzyme and inhibits it. Oxypurinol, a purine inhibitor of xanthine oxidase, inhibits the reduced form of the enzyme only. Febuxostat does not inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.
Chronic management of hyperuricemia in patients with Gout.
As directed by the physician.
Hypersensitivity Co-administration with azathioprine, mercaptopurine, or theophylline.
Nausea, Joint Pain, Rash, Gout Flare-Ups.
Store in a cool and dry place. Protect from light.
10x1x10 tablets in a cardboard carton